We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 2,060

China new healthcare reform 2020 - ten things to know
  • Norton Rose Fulbright LLP
  • China
  • May 20 2015

China recently announced a new five year road-map for reform of its healthcare sector. The National Planning Guideline for the Healthcare Service


Technology outpacing regulation
  • Freshfields Bruckhaus Deringer LLP
  • China, European Union, USA
  • May 18 2015

Healthcare services and products are highly regulated throughout their life cycle - from product development to market entry, distribution and


Novartis Agrees to Settle Bribery Charges Against Chinese Subsidiaries for $25 Million
  • Ropes & Gray LLP
  • China, USA
  • April 4 2016

On March 23, 2015, Swiss-based pharmaceutical company Novartis AG (“Novartis”) reached a civil settlement with the United States Securities and


Further opening of the Chinese lifesciences sector in 2016
  • CMS Cameron McKenna
  • China
  • January 29 2016

China’s "opening up" has gained further momentum in the lifesciences sector with the Notice of Health and Family Planning Working Essentials for 2016


Antitrust in China's pharma sector Bengbu action following big-bang reform
  • Hogan Lovells
  • China
  • September 1 2015

On 26 August 2015, the National Development and Reform Commission ("NDRC") made public its first antitrust enforcement decision in the pharmaceutical


China releases new Regulations on donations to healthcare entities: implications for multinational healthcare companies
  • Paul Hastings LLP
  • China, USA
  • November 10 2015

In recent years, fighting corruption in the healthcare sector both domestically and abroad has been a major focus of U.S. regulators. In China


A comparison of European and Chinese regulation of biosimilar products
  • CMS Cameron McKenna
  • China, European Union
  • October 29 2015

Since its first biosimilar guidelines were released in 2005, the European Medicines Agency (“EMA”) has developed a detailed set of guidelines


China: CFDA implements new review and approval system for generic drugs
  • Bird & Bird
  • China
  • March 28 2016

The Chinese drug regulatory authority (the “CFDA”) has recently issued two policy documents to reform the review and approval system for drugs and


CFDA proposes new initiatives to improve and reform its drug review system
  • Sidley Austin LLP
  • China
  • August 4 2015

On July 31, 2015, the China Food and Drug Administration (CFDA) published a draft policy paper for public comments by August 15, 2015, proposing new


Reform on drugs pricing
  • CMS, China
  • China
  • June 3 2015

Focusing on the reform on drugs pricing, on 26 April 2015, the General Office of the State Council released the Circular on Work Summary for 2014 and